2022+ADA/EASD共識報告:2型糖尿病高血糖的管理_第1頁
2022+ADA/EASD共識報告:2型糖尿病高血糖的管理_第2頁
2022+ADA/EASD共識報告:2型糖尿病高血糖的管理_第3頁
2022+ADA/EASD共識報告:2型糖尿病高血糖的管理_第4頁
2022+ADA/EASD共識報告:2型糖尿病高血糖的管理_第5頁
已閱讀5頁,還剩78頁未讀 繼續(xù)免費閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)

文檔簡介

Diabetologia

/10.1007/s00125-022-05787-2

CONSENSUSREPORT

Managementofhyperglycaemiaintype2diabetes,2022.AconsensusreportbytheAmericanDiabetesAssociation(ADA)andtheEuropeanAssociationfortheStudyofDiabetes(EASD)

MelanieJ.Davies1,2&VanitaR.Aroda3&BillyS.Collins4&RobertA.Gabbay5&JenniferGreen6&

NisaM.Maruthur7&SylviaE.Rosas8&StefanoDelPrato9&ChantalMathieu10&GeltrudeMingrone11,12,13&PeterRossing14,15&TsvetalinaTankova16&ApostolosTsapas17,18&JohnB.Buse19

Received:2August2022/Accepted:18August2022

#AmericanDiabetesAssociationandtheEuropeanAssociationfortheStudyofDiabetes2022

Abstract

TheAmericanDiabetesAssociationandtheEuropeanAssociationfortheStudyofDiabetesconvenedapaneltoupdatethepreviousconsensusstatementsonthemanagementofhyperglycaemiaintype2diabetesinadults,publishedsince2006andlastupdatedin2019.ThetargetaudienceisthefullspectrumoftheprofessionalhealthcareteamprovidingdiabetescareintheUSAandEurope.Asystematicexaminationofpublicationssince2018informednewrecommendations.Theseincludeadditionalfocusonsocialdeterminantsofhealth,thehealthcaresystemandphysicalactivitybehavioursincludingsleep.Thereisagreateremphasisonweightmanagementaspartoftheholisticapproachtodiabetesmanagement.Theresultsofcardiovascularandkidneyoutcomestrialsinvolvingsodium–glucosecotransporter-2inhibitorsandglucagon-likepeptide-1receptoragonists,includingassessmentofsubgroups,informbroaderrecommendationsforcardiorenalprotectioninpeoplewithdiabetesathighriskofcardiorenaldisease.Afterasummarylistingofconsensusrecommendations,practicaltipsforimplementationareprovided.

KeywordsCardiovasculardisease.Chronickidneydisease.Glucose-loweringtherapy.Guidelines.Heartfailure.Holisticcare.Person-centredcare.Socialdeterminantsofhealth.Type2diabetesmellitus.Weightmanagement

Abbreviations

ThisarticleisbeingsimultaneouslypublishedinDiabetologia(

https://

/10.1007/s00125-022-05787-2

)andDiabetesCare(

https://doi

.

org/10.2337/dci22-0034

)bytheEuropeanAssociationfortheStudyofDiabetesandAmericanDiabetesAssociation.

Aconsensusreportofaparticulartopiccontainsacomprehensiveexaminationandisauthoredbyanexpertpanelandrepresentsthepanel’scollectiveanalysis,evaluationandopinion.MJDandJBBwereco-chairsfortheConsensusReportWritingGroup.VRA,BSC,RAG,JG,NMMandSERwerethewritinggroupmembersforADA.SDP,CM,GM,PR,TTandATwerethewritinggroupmembersforEASD.ThearticlewasreviewedforEASDbyitsCommitteeonClinicalAffairsandapprovedbyitsExecutiveBoard.ThearticlewasreviewedforADAbyitsProfessionalPracticeCommittee.

*MelanieJ.Davies(forDiabetologia)melanie.davies@uhl-tr.nhs.uk

*JohnB.Buse(forDiabetesCare)jbuse@

Extendedauthorinformationavailableonthelastpageofthearticle

BGM

CGM

CSII

CVOT

DKA

DPP-4i

DSMES

ETD

GIPGLP-1RAHF

HHF

MACE

MNT

NAFLD

NASH

SGLT1i

Bloodglucosemonitoring

Continuousglucosemonitoring

ContinuoussubcutaneousinsulininfusionCardiovascularoutcomestrial

Diabeticketoacidosis

Dipeptidylpeptidase-4inhibitors

Diabetesself-managementeducationandsupport

Estimatedtreatmentdifference

Glucose-dependentinsulinotropicpolypeptideGlucagon-likepeptide-1receptoragonist(s)Heartfailure

Hospitalisationforheartfailure

Majoradversecardiovascularevents

Medicalnutritiontherapy

Non-alcoholicfattyliverdisease

Non-alcoholicsteatohepatitisSodium–glucosecotransporter-1inhibitor

Diabetologia

SGLT2i

TZD

UACR

Sodium–glucosecotransporter-2inhibitor(s)Thiazolidinedione

Urinaryalbumin/creatinineratio

Introduction

Type2diabetesisachroniccomplexdiseaseandmanagementrequiresmultifactorialbehaviouralandpharmacologicaltreat-mentstopreventordelaycomplicationsandmaintainqualityoflife(Fig.

1

).Thisincludesmanagementofbloodglucoselevels,weight,cardiovascularriskfactors,comorbiditiesandcomplications.Thisnecessitatesthatcarebedeliveredinanorganisedandstructuredway,suchasdescribedinthechroniccaremodel,andincludesaperson-centredapproachtoenhanceengagementinself-careactivities[

1

].Carefulconsid-erationofsocialdeterminantsofhealthandthepreferencesofpeoplelivingwithdiabetesmustinformindividualisationoftreatmentgoalsandstrategies[

2

].

Thisconsensusreportaddressestheapproachestomanage-mentofbloodglucoselevelsinnon-pregnantadultswithtype2diabetes.TheprinciplesandapproachforachievingthisaresummarisedinFig.

1

.Theserecommendationsarenotgener-allyapplicabletoindividualswithdiabetesduetoothercauses,forexamplemonogenicdiabetes,secondarydiabetesandtype1diabetes,ortochildren.

Datasources,searchesandstudyselection

ThewritinggroupmemberswereappointedbytheADAandEASD.Thegrouplargelyworkedvirtuallywithregulartelecon-ferencesfromSeptember2021,a3dayworkshopinJanuary2022andaface-to-face2daymeetinginApril2022.Thewritinggroupacceptedthe2012[

3

],2015[

4

],2018[

5

]and2019[

6

]editionsofthisconsensusreportasastartingpoint.Toidentifynewerevidence,asearchwasconductedonPubMedforRCTs,systematicreviewsandmeta-analysespublishedinEnglishbetween28January2018and13June2022;eligiblepublica-tionsexaminedtheeffectivenessorsafetyofpharmacologicalornon-pharmacologicalinterventionsinadultswithtype2diabe-tes.Referencelistsineligiblereportswerescannedtoidentifyadditionalrelevantarticles.Detailsofthekeywordsandthesearchstrategyareavailableat

/

datasets/h5rcnxpk8w/2

.Papersweregroupedaccordingtosubjectandtheauthorsreviewedthisnewevidence.Up-to-datemeta-analysesevaluatingtheeffectsoftherapeuticinterven-tionsacrossclinicallyimportantsubgrouppopulationswereassessedintermsoftheircredibilityusingrelevantguidance[

7

,

8

].EvidenceappraisalwasinformedbytheGradingofRecommendationsAssessment,DevelopmentandEvaluation(GRADE)guidelinesontheformulationofclinicalpracticerecommendations[

9

,

10

].Thedraftconsensus

recommendationswereevaluatedbyinvitedreviewersandpresentedforpubliccomment.Suggestionswereincorporatedasdeemedappropriatebytheauthors(seeAcknowledgements).Nevertheless,althoughevidencebasedwithstakeholderinput,therecommendationspresentedhereinreflectthevaluesandpreferencesoftheconsensusgroup.

Therationale,importanceandcontext

ofglucose-loweringtreatment

Fundamentalaspectsofdiabetescareincludepromotinghealthybehaviours,throughmedicalnutritiontherapy(MNT),physicalactivityandpsychologicalsupport,aswellasweightmanagementandtobacco/substanceabusecounsel-lingasneeded.Thisisoftendeliveredinthecontextofdiabe-tesself-managementeducationandsupport(DSMES).Theexpandingnumberofglucose-loweringinterventions—frombehaviouralinterventionstopharmacologicalinterventions,devicesandsurgery—andgrowinginformationabouttheirbenefitsandrisksprovidemoreoptionsforpeoplewithdiabe-tesandprovidersbutcomplicatedecisionmaking.Thedemonstratedbenefitsforhigh-riskindividualswithathero-scleroticCVD,heartfailure(HF)orchronickidneydisease(CKD)affordedbytheglucagon-likepeptide-1receptoragonists(GLP-1RA)andsodium–glucosecotransporter-2inhibitors(SGLT2i)provideimportantprogressintreatmentaimedatreducingtheprogressionandburdenofdiabetesanditscomplications.Thesebenefitsarelargelyindependentoftheirglucose-loweringeffects.Thesetreatmentswereinitiallyintroducedasglucose-loweringagentsbutarenowalsoprescribedfororganprotection.Inthisconsensusreport,wesummarisealargebodyofrecentevidenceforpractitionersintheUSAandEuropewiththeaimofsimplifyingclinicaldeci-sionmakingandfocusingoureffortsonprovidingholisticperson-centredcare.

Attainingrecommendedglycaemictargetsyieldssubstan-tialandenduringreductionsintheonsetandprogressionofmicrovascularcomplications[

11

,

12

]andearlyinterventionisessential[

13

].Thegreatestabsoluteriskreductioncomesfromimprovingveryelevatedglycaemiclevels,andamoremodestreductionresultsfromnearnormalisationofplasmaglucoselevels[

2

,

14

].Theimpactofglucosecontrolonmacrovascularcomplicationsislesscertainbutissupportedbymultiplemeta-analysesandepidemiologicalstudies.Becausethebene-fitsofintensiveglucosecontrolemergeslowlywhiletheharmscanbeimmediate,peoplewithlongerlifeexpectancyhavemoretogainfromearlyintensiveglycaemicmanage-ment.AreasonableHbA1ctargetformostnon-pregnantadultswithsufficientlifeexpectancytoseemicrovascularbenefits(generally~10years)isaround53mmol/mol(7%)orless[

2

].AimingforalowerHbA1clevelthanthismayhavevalueifitcanbeachievedsafelywithoutsignificanthypoglycaemiaor

Fig.1Decisioncycleforperson-centredglycaemicmanagementintype2diabetes.Adaptedfrom[5]withpermissionfromSpringerNature,?EuropeanAssociationfortheStudyofDiabetesand

AmericanDiabetesAssociation,2018

Diabetologia

Diabetologia

otheradversetreatmenteffects.Alowertargetmaybereason-able,particularlywhenusingpharmacologicalagentsthatarenotassociatedwithhypoglycaemicrisk.Highertargetscanbeappropriateincasesoflimitedlifeexpectancy,advancedcomplicationsorpoortolerabilityorifotherfactorssuchasfrailtyarepresent.Thus,glycaemictreatmenttargetsshouldbetailoredbasedonanindividual’spreferencesandcharac-teristics,includingyoungerage(i.e.age<40years),riskofcomplications,frailtyandcomorbidconditions[

2

,

15

17

],andtheimpactofthesefeaturesontheriskofadverseeffectsoftherapy(e.g.hypoglycaemiaandweightgain).

Principlesofcare

Languagematters

Communicationbetweenpeoplelivingwithtype2diabetesandhealthcareteammembersisatthecoreofintegratedcare,andcliniciansmustrecognisehowlanguagematters.Languageindiabetescareshouldbeneutral,freeofstigmaandbasedonfacts;bestrengths-based(focusonwhatiswork-ing),respectfulandinclusive;encouragecollaboration;andbeperson-centred[

18

].Peoplelivingwithdiabetesshouldnotbereferredtoas‘diabetics’ordescribedas‘non-compliant’orblamedfortheirhealthcondition.

Diabetesself-managementeducationandsupport

DSMESisakeyintervention,asimportanttothetreatmentplanastheselectionofpharmacotherapy[

19

21

].DSMESiscentraltoestablishingandimplementingtheprinciplesofcare(Fig.

1

).DSMESprogrammesusuallyinvolveface-to-facecontactingrouporindividualsessionswithtrainededucators,andkeycomponentsofDSMESareshowninSupplementaryTable1[

19

24

].Giventheever-changingnatureoftype2diabetes,DSMESshouldbeofferedonanongoingbasis.CriticaljunctureswhenDSMESshouldbeprovidedincludeatdiagnosis,annually,whencomplicationsarise,andduringtransitionsinlifeandcare(SupplementaryTable1)[

22

].

High-qualityevidencehasconsistentlyshownthatDSMESsignificantlyimprovesknowledge,glycaemiclevelsandclin- icalandpsychologicaloutcomes,reduceshospitaladmissionsandall-causemortalityandiscost-effective[

22

,

25

30

].DSMESisdeliveredthroughstructurededucationalprogrammesprovidedbytraineddiabetescareandeducationspecialists(termedDCESintheUSA;hereafterreferredtoas‘diabeteseducators’)thatfocusparticularlyonthefollowing: lifestylebehaviours(healthyeating,physicalactivityandweightmanagement),medication-takingbehaviour,self-monitoringwhenneeded,self-efficacy,copingandproblemsolving.

Importantly,DSMESistailoredtotheindividual’scontext,whichincludestheirbeliefsandpreferences.DSMEScanbeprovidedusingmultipleapproachesandinavarietyofsettings[

20

,

31

]anditisimportantforthecareteamtoknowhowtoaccesslocalDSMESresources.DSMESsupportsthepsycho-socialcareofpeoplewithdiabetesbutisnotareplacementforreferralformentalhealthserviceswhentheyarewarranted,forexamplewhendiabetesdistressremainsafterDSMES.Psychiatricdisorders,includingdisorderedeatingbehaviours,arecommon,oftenunrecognisedandcontributetopooroutcomesindiabetes[

32

].

ThebestoutcomesfromDSMESareachievedthroughprogrammeswithatheory-basedandstructuredcurriculumandwithcontacttimeofover10h[

26

].Whileonlineprogrammesmayreinforcelearning,acomprehensiveapproachtoeducationusingmultiplemethodsmaybemoreeffective[

26

].Emergingevidencedemonstratesthebenefitsoftelehealthorweb-basedDSMESprogrammes[

33

]andthesewereusedwithsuccessduringtheCOVID-19pandemic[

34

36

].Technologiessuchasmobileapps,simulationtools,digitalcoachinganddigitalself-managementinterventions

canbeusedtodeliverDSMESandextenditsreachtoa

broadersegmentofthepopulationwithdiabetesandprovidecomparableorevenbetteroutcomes[

37

].GreaterHbA1creductionsaredemonstratedwithincreasedengagementofpeoplewithdiabetes[

35

,

38

].However,datafromtrialsofdigitalstrategiestosupportbehaviourchangearestillprelim-inaryinnatureandquiteheterogeneous[

22

,

37

].

Individualisedandpersonalisedapproach

Type2diabetesisaveryheterogeneousdiseasewithvariableageatonset,relateddegreeofobesity,insulinresistanceandtendencytodevelopcomplications[

39

,

40

].Providingperson-centredcarethataddressesmultimorbidityandisrespectfulofandresponsivetoindividualpreferencesandbarriers,includingthedifferentialcostsoftherapies,isessen-tialforeffectivediabetesmanagement[

41

].Shareddecisionmaking,facilitatedbydecisionaidsthatshowtheabsolutebenefitandriskofalternativetreatmentoptions,isausefulstrategytodeterminethebesttreatmentcourseforanindivid-ual[

42

45

].WithcompellingindicationsfortherapiessuchasSGLT2iandGLP-1RAforhigh-riskindividualswithCVD,HForCKD,shareddecisionmakingisessentialtocontextualisetheevidenceonbenefits,safetyandrisks.Providersshouldevaluatetheimpactofanysuggestedinter-ventioninthecontextofcognitiveimpairment,limitedlitera-cy,distinctculturalbeliefsandindividualfearsorhealthconcerns.Thehealthcaresystemisanimportantfactorintheimplementation,evaluationanddevelopmentofthepersonalisedapproach.Furthermore,socialdeterminantsofhealth—oftenoutofdirectcontroloftheindividualandpoten-tiallyrepresentinglifelongrisk—contributetomedicaland

Diabetologia

psychosocialoutcomesandmustbeaddressedtoimprovehealthoutcomes.Fivesocialdeterminantsofhealthareashavebeenidentified:socioeconomicstatus(education,incomeandoccupation),livingandworkingconditions,multisectordomains(e.g.housing,educationandcriminaljusticesystem),socioculturalcontext(e.g.sharedculturalvalues,practicesandexperiences)andsociopoliticalcontext(e.g.societalandpolit-icalnormsthatarerootcauseideologiesandpoliciesunderly-inghealthdisparities)[

46

].Moregranularityonsocialdetermi-nantsofhealthastheypertaintodiabetesisprovidedinarecentADAreview[

47

],withaparticularfocusontheissuesfacedintheAfricanAmericanpopulationprovidedinasubsequentreport[

48

].Environmental,social,behaviouralandemotionalfactors,knownaspsychosocialfactors,alsoinfluencelivingwithdiabetesandachievingsatisfactorymedicaloutcomesandpsychologicalwell-being.Thus,thesemultifaceteddomains(heterogeneityacrossindividualcharacteristics,socialdeterminantsofhealthandpsychosocialfactors)challengeindi-vidualswithdiabetes,theirfamiliesandtheirproviderswhenattemptingtointegratediabetescareintodailylife[

49

].

Currentprinciplesof,andapproachesto,person-centredcareindiabetes(Fig.

1

)includeassessingkeycharacteristicsandpreferencestodetermineindividualisedtreatmentgoalsandstrategies.Suchcharacteristicsincludecomorbidities,clinicalcharacteristicsandcompellingindicationsforGLP-1RAorSGLT2ifororganprotection[

6

].

Weightreductionasatargetedintervention

WeightreductionhasmostlybeenseenasastrategytoimproveHbA1candreducetheriskforweight-relatedcompli-cations.However,itwasrecentlysuggestedthatweightlossof5–15%shouldbeaprimarytargetofmanagementformanypeoplelivingwithtype2diabetes[

50

].Ahighermagnitudeofweightlossconfersbetteroutcomes.Weightlossof5–10%confersmetabolicimprovement;weightlossof10–15%ormorecanhaveadisease-modifyingeffectandleadtoremis-sionofdiabetes[

50

],definedasnormalbloodglucoselevelsfor3monthsormoreintheabsenceofpharmacologicalther-apyina2021consensusreport[

51

].Weightlossmayexertbenefitsthatextendbeyondglycaemicmanagementtoimproveriskfactorsforcardiometabolicdiseaseandqualityoflife[

50

].

Glucosemanagement:monitoring

GlycaemicmanagementisprimarilyassessedwiththeHbA1ctest,whichwasthemeasureusedintrialsdemonstratingthebenefitsofglucoselowering[

2

,

52

].Aswithanylaboratorytest,HbA1cmeasurementhaslimitations[

2

,

52

].TheremaybediscrepanciesbetweenHbA1cresultsandanindividual’struemeanbloodglucoselevels,particularlyincertainracialandethnicgroupsandinconditionsthataltererythrocyte

turnover,suchasanaemia,end-stagekidneydisease(espe-ciallywitherythropoietintherapy)andpregnancy,orifanHbA1cassayinsensitivetohaemoglobinvariantsisusedinsomeonewithahaemoglobinopathy.DiscrepanciesbetweenmeasuredHbA1clevelsandmeasuredorreportedglucoselevelsshouldpromptconsiderationthatoneofthesemaynotbereliable[

52

,

53

].

Regularbloodglucosemonitoring(BGM)mayhelpwithself-managementandmedicationadjustment,particularlyinindividualstakinginsulin.BGMplansshouldbeindividualised.Peoplewithtype2diabetesandthehealthcareteamshouldusethemonitoringdatainaneffectiveandtimelymanner.Inpeoplewithtype2diabetesnotusinginsulin,routineglucosemonitoringisoflimitedadditionalclinicalbenefitwhileaddingburdenandcost[

54

,

55

].However,forsomeindividuals,glucosemonitoringcanprovideinsightintotheimpactoflifestyleandmedicationmanagementonbloodglucoseandsymptoms,particularlywhencombinedwitheducationandsupport[

53

].Technologiessuchasintermittent-lyscannedorreal-timecontinuousglucosemonitoring(CGM)providemoreinformationandmaybeusefulforpeoplewithtype2diabetes,particularlyinthosetreatedwithinsulin[

53

,

56

].

WhenusingCGM,standardised,singleglucosereports,suchastheambulatoryglucoseprofile,canbeuploadedfromCGMdevices.TheyshouldbeconsideredasstandardmetricsforallCGMdevicesandprovidevisualcuesformanagementopportunities.TimeinrangeisdefinedasthepercentageoftimethatCGMreadingsareintherange3.9–10.0mmol/l(70–180mg/dl).Timeinrangeisassociatedwiththeriskofmicrovascularcomplicationsandcanbeusedforassessmentofglycaemicmanagement[

57

].Additionally,timeaboveandbelowrangeareusefulvariablesfortheeval-uationoftreatmentregimens.Particularattentiontominimisingthetimebelowrangeinthosewithhypoglycaemiaunawarenessmayconveybenefit.Ifusingtheambulatoryglucoseprofiletoassessglycaemicmanagement,agoalparal-leltoanHbA1clevelof<53mmol/mol(<7%)formanyistimeinrangeof>70%,withadditionalrecommendationstoaimfortimebelowrangeof<4%andtimeat<3.0mmol/l(<54mg/dl)of<1%[

2

].

Treatmentbehaviours,persistenceandadherence

Suboptimalmedication-takingbehaviourandlowratesofcontinuedmedicationuse,orwhatistermed‘persistencetotherapyplans’affectsalmosthalfofpeoplewithtype2diabe-tes,leadingtosuboptimalglycaemicandCVDriskfactorcontrolaswellasincreasedrisksofdiabetescomplications,mortalityandhospitaladmissionsandincreasedhealthcarecosts[

58

62

].Althoughthisconsensusreportfocusesonmedication-takingbehaviour,theprinciplesarepertinenttoallaspectsofdiabetescare.Multiplefactorscontributeto

Diabetologia

inconsistentmedicationuseandtreatmentdiscontinuationamongpeoplewithdiabetes,includingperceivedlackofmedicationefficacy,fearofhypoglycaemia,lackofaccesstomedicationandadverseeffectsofmedication[

63

].Focusingonfacilitatorsofadherence,suchassocial/family/providersupport,motivation,educationandaccesstomedi-cations/foods,canprovidebenefits[

64

].Observedratesofmedicationadherenceandpersistencevaryacrossmedicationclassesandbetweenagents;carefulconsiderationofthesedifferencesmayhelpimproveoutcomes[

61

].Ultimately,individualpreferencesaremajorfactorsdrivingthechoiceofmedications.Evenwhenclinicalcharacteristicssuggesttheuseofaparticularmedicationbasedontheavailableevidencefromclinicaltrials,preferencesregardingrouteofadministra-tion,injectiondevices,sideeffectsorcostmaypreventusebysomeindividuals[

65

].

Therapeuticinertia

Therapeutic(orclinical)inertiadescribesalackoftreatmentintensificationwhentargetsorgoalsarenotmet.Italsoincludesfailuretode-intensifymanagementwhenpeopleareovertreated.Thecausesoftherapeuticinertiaaremultifactori-al,occurringatthelevelsofthepractitioner,personwithdiabetesand/orhealthcaresystem[

66

].Interventionstargetingtherapeuticinertiahavefacilitatedimprovementsinglycaemicmanagementandtimelyinsulinintensification[

67

,

68

].Forexample,theinvolvementofmultidisciplinaryteamsthatincludenon-physicianproviderswithauthorisationtoprescribe(e.g.pharmacists,specialistnursesandadvancedpracticeproviders)mayreducetherapeuticinertia[

69

,

70

].

Therapeuticoptions:lifestyleandhealthybehaviour,weightmanagement

andpharmacotherapyforthetreatment

oftype2diabetes

Thissectionsummarisesthelifestyleandbehaviouralther-apy,weightmanagementinterventionsandpharmacother-apythatsupportglycaemicmanagementinpeoplewithtype2diabetes.SpecificpharmacologicaltreatmentoptionsaresummarisedinTable

1

.AdditionaldetailsareavailableinthepreviousADA/EASDconsensusreportandupdate[

5

,

6

]andtheADA’s2022Standardsofmedicalcareindiabetes[

71

].

Nutritiontherapy

Nutritiontherapyisintegraltodiabetesmanagement,withgoalsofpromotingandsupportinghealthyeatingpatterns,addressingindividualnutritionneeds,maintainingtheplea-sureofeatingandprovidingthepersonwithdiabeteswith

thetoolsfordevelopinghealthyeating[

22

].MNTprovidedbyaregistereddietitian/registereddietitiannutritionistcomplementsDSMES,cansignificantlyreduceHbA1candcanhelpprevent,delayandtreatcomorbiditiesrelatedtodiabetes[

19

].TwocoredimensionsofMNTthatcanimproveglycaemicmanagementincludedietaryqualityandenergyrestriction.

Dietaryqualityandeatingpatterns

Thereisnosingleratioofcarbohydrate,proteinsandfatintakethatisoptimalforeverypersonwithtype2diabe-tes.Instead,individuallyselectedeatingpatternsthatemphasisefoodswithdemonstratedhealthbenefits,mini-misefoodsshowntobeharmfulandaccommodateindi-vidualpreferenceswiththegoalofidentifyinghealthydietaryhabitsthatarefeasibleandsustainablearerecom-mended.Anetenergydeficitthatcanbemaintainedisimportantforweightloss[

5

,

6

,

22

,

72

74

].

Anetworkanalysiscomparingtrialsofninedietaryapproachesof>12weeks’durationdemonstratedreduc-tionsinHbA1cfrom?9to?5.1mmol/mol(?0.82%to?0.47%),withallapproachescomparedwithacontroldiet.GreaterglycaemicbenefitswereseenwiththeMediterraneandietandlowcarbohydratediet[

75

].Thegreaterglycaemicbenefitsoflowcarbohydratediets(<26%ofenergy)at3and6monthsarenotevidentwithlongerfollow-up[

72

].Inasystematicreviewoftrialsof>6months’duration,comparedwithalow-fatdiet,theMediterraneandietdemonstratedgreaterreductionsinbodyweightandHbA1clevels,delayedtherequirementfordiabetesmedicationandprovidedbenefitsforcardio-vascularhealth[

76

,

77

].Similarbenefitshavebeenascribedtoveganandvegetariandiets[

78

].

Therehasbeenincreasedinterestintime-restrictedeatingandintermittentfastingtoimprovemetabolicvari-ables,althoughwithmixed,andmodest,results.Inameta-analysistherewerenodifferencesintheeffectofintermittentfastingandcontinuousenergyrestrictiononHbA1c,withintermittentfastinghavingamodesteffectonweight(?1.70kg)[

79

].Ina12monthRCTinadultswithtype2diabetescomparingintermittentenergyrestriction(2092–2510kJ[500–600kcal]dietfor2non-consecutivedays/weekfollowedbytheusualdietfor5days/week)withcontinuousenergyrestriction(5021–6276kJ[1200–1500kcal]dietfor7days/week),glycaemicimprovementswerecomparablebetweenthetwogroups.At24months’follow-up,HbA1cincreasedinbothgroupstoabovebaseline[

80

],whileweightloss(?3.9kg)wasmaintainedinbothgroups[

81

].Fastingmayincreasetheratesofhypoglycaemiainthosetreatedwithinsulinandsulfonylureas,highlightingtheneedforindividualised

Diabetologia

Table1Medicationsforloweringglucose,summaryofcharacteristics

Diabetologia

educationandproactivemedicationmanagementduringsignificantdietarychanges[

82

].

Non-surgicalenergyrestrictionforweightloss

Anoverallhealthyeatingplanthatresultsinanenergydeficit,inconjunctionwithmedicationsand/ormetabolicsurgeryasindividuallyappropriate,shouldbeconsideredtosupportglycaemicandweightmanagementgo

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
  • 6. 下載文件中如有侵權(quán)或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

最新文檔

評論

0/150

提交評論